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Background: Inducing endoplasmic reticulum (ER) stress is a novel strategy used to treat malignancies. Inhibition
of histone deacetylase (HDAC) 6 by the HDAC inhibitor panobinostat hinders the refolding of unfolded proteins
by increasing the acetylation of heat shock protein 90. We investigated whether combining panobinostat with the
proteasome inhibitor bortezomib would kill cancer cells effectively by inhibiting the degradation of these unfolded
proteins, thereby causing ubiquitinated proteins to accumulate and induce ER stress.
Methods: Caki-1, ACHN, and 769-P cells were treated with panobinostat and/or bortezomib. Cell viability,
clonogenicity, and induction of apoptosis were evaluated. The in vivo efficacy of the combination was evaluated
using a murine subcutaneous xenograft model. The combination-induced ER stress and ubiquitinated protein
accumulation were assessed.
Results: The combination of panobinostat and bortezomib induced apoptosis and inhibited renal cancer growth
synergistically (combination indexes <1). It also suppressed colony formation significantly (p <0.05). In a murine
subcutaneous tumor model, a 10-day treatment was well tolerated and inhibited tumor growth significantly
(p <0.05). Enhanced acetylation of the HDAC6 substrate alpha-tubulin was consistent with the suppression of
HDAC6 activity by panobinostat, and the combination was shown to induce ER stress and ubiquitinated protein
accumulation synergistically.
Conclusions: Panobinostat inhibits renal cancer growth by synergizing with bortezomib to induce ER stress and
ubiquitinated protein accumulation. The current study provides a basis for testing the combination in patients
with advanced renal cancer.
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Renal cancer, Combination therapyBackground
A new therapeutic approach to advanced renal cancer is
urgently needed because there is presently no curative
treatment, and one innovative treatment strategy used
against cancer is to induce endoplasmic reticulum (ER)
stress and ubiquitinated protein accumulation [1]. Protein
unfolding rates that exceed the capacity of protein chaper-
ones cause ER stress, and chronic or unresolved ER stress* Correspondence: zenpaku@ndmc.ac.jp
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unless otherwise stated.can lead to apoptosis [2]. On the other hand, unfolded
proteins that fail to be repaired by chaperones are then
ubiquitinated and the accumulation of these ubiquitinated
proteins is also cytotoxic [3].
Histone deacetylase (HDAC) 6 inhibition acetylates
heat shock protein (HSP) 90 and suppresses its function
as a molecular chaperon, increasing the amount of un-
folded proteins in the cell [4]. Because these unfolded
proteins are then ubiquitinated and degraded by the pro-
teasome [5], HDAC6 inhibition alone is thought to cause
no or only slight ER stress and ubiquitinated proteind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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thought that combining an HDAC inhibitor with the
proteasome inhibitor bortezomib would cause ER stress
and ubiquitinated protein accumulation synergistically
because the increased ubiquitinated proteins would not
be degraded by the inhibited proteasome.
Panobinostat is a novel HDAC inhibitor that has been
clinically tested not only in patients with hematological
malignancies [6,7] but also patients with solid tumors,
including renal cell carcinoma [8,9]. Bortezomib has
been approved by the FDA and widely used for the
treatment of multiple myeloma [10].
In the present study using renal cancer cells, we inves-
tigated whether the combination of panobinostat and
bortezomib induces ER stress and ubiquitinated protein




Renal cancer cell lines (Caki-1, ACHN, and 769-P) were
purchased from the American Type Culture Collection
(Rockville, MD). Caki-1 cells were maintained in MEM,
ACHN cells in DMEM, and 769-P cells in RPMI medium,
all supplemented with 10% fetal bovine serum and 0.3%
penicillin-streptomycin (Invitrogen, Carlsbad, CA).
Reagents
Panobinostat and bortezomib were obtained from
Cayman Chemical (Ann Arbor, MI) and LC Laboratories
(Woburn, MA), respectively, dissolved in dimethyl sulfox-
ide (DMSO), and stored at −20°C until use.
Evaluating effect of the combination of panobinostat and
bortezomib on cell viability and colony formation
For cell viability assay, 5 × 103 cells were plated in a
96-well culture plate one day before treatment and
treated with panobinostat (25–50 nM) and/or bortezomib
(5–15 nM) for 48 hours. Cell viability was evaluated by
MTS assay (Promega, Madison, WI) according to the
manufacturer’s protocol. For colony formation assay, 1 ×
102 cells were plated in 6-well plates one day before
treatment and cultured for 48 hours in media containing
50 nM panobinostat and/or 10 nM bortezomib. They
were then given fresh media and allowed to grow for 1–2
weeks, depending on the cell line. The number of colonies
was then counted after fixing the cells with 100% metha-
nol and staining them with Giemsa’s solution.
Evaluating effect of the combination of panobinostat and
bortezomib on induction of apoptosis
1.5 × 105 cells were plated in a 6-well culture plate one
day before being cultured for 48 hours in medium con-
taining 50 nM panobinostat and/or 10 nM bortezomib.Induction of apoptosis was evaluated, using flow cytom-
etry, by annexin-V assay and cell cycle analysis. For
annexin-V assay the harvested cells were stained with
annexin V according to the manufacturer’s protocol
(Beckman Coulter, Marseille, France). For cell cycle
analysis the harvested cells were resuspended in citrate
buffer and stained with propidium iodide. They were
then analyzed by flow cytometry using CellQuest Pro
Software (BD Biosciences, San Jose, CA).
Murine xenograft model
The animal protocol for this experiment has been ap-
proved by the institutional Animal Care and Use Commit-
tee of National Defense Medical College. 5-week-old male
nude mice (strain BALB/c Slc-nu/nu) were purchased
from CLEA (Tokyo, Japan). The animals were housed
under pathogen-free conditions and had access to stand-
ard food and water ad libitum. 1 × 107 Caki-1 cells were
subcutaneously injected into the flank and treatments
were initiated 4 days after the injection (day 1), when the
tumors became palpable. The mice were divided into 4
groups of 5, the control group receiving intraperitoneal
injections of DMSO and the other groups receiving either
panobinostat (2 mg/kg) or bortezomib (60 μg/kg) or
both. Injections were given once a day, 5 days a week,
for 2 weeks. Tumor volume was estimated as one half of
the product of the length and the square of the width (i.e.,
volume = 0.5 × length × width2).
Western blotting
Cells were treated under the indicated conditions for
48 hours and whole-cell lysates were obtained using
RIPA buffer. Equal amounts of protein were subjected to
SDS-PAGE and transferred onto nitrocellulose mem-
branes that were then probed with antibodies specific
for glucose-regulated protein (GRP) 78, ubiquitin (Santa
Cruz Biotechnology, Santa Cruz, CA), actin (Millipore,
Billerica, MA), HSP70, endoplasmic reticulum resident
protein (ERp) 44, endoplasmic oxidoreductin-1-like pro-
tein (Ero1-L)α, cleaved poly(ADP-ribose) polymerase
(PARP) (Cell Signaling Technology, Danvers, MA),
acetylated α-tubulin (Enzo Life Sciences, Farmingdale,
NY), and acetylated histone (Abcam, Cambridge, UK).
This probing was followed by treatment with horse-
radish-peroxidase-tagged secondary antibodies (Bio-Rad,
Hercules, CA) and visualization by chemiluminescence
(ECL, Amersham, Piscataway, NJ).
Statistical analyses
The combination indexes were calculated using the
Chou-Talalay method and CalcuSyn software (Biosoft,
Cambridge, UK). The statistical significance of observed
differences between samples was determined using the
Mann-Whitney U test (StatView software, SAS Institute,
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p <0.05.
Results
Combination of panobinostat and bortezomib inhibited
renal cancer growth synergistically
We first investigated the combined effect of panobino-
stat and bortezomib on renal cancer cell viability by
MTS assay. Panobinostat and bortezomib each inhibited
the growth of renal cancer cells in a dose-dependent
fashion, and the combination did so more effectively
than either did by itself (Figure 1A). Analysis using the
Chou-Talalay method indicated that the effect of the
combination was synergistic (combination index <1) in
many of the treatment conditions (Table 1). We then
investigated whether the combination affects the clono-
genic survival of renal cancer cells. Colony formationFigure 1 The combination of panobinostat and bortezomib inhibited
n = 6) after cells were treated for 48 hours either with bortezomib or panobin
formation assay results (mean ± SD, n = 3) after 1–2 week incubation in contro
bortezomib (B). *p = 0.0495; **p = 0.0463.assay revealed that the combination suppressed colony
formation significantly and did so significantly more than
did either panobinostat or bortezomib alone (Figure 1B).
We also used a subcutaneous xenograft mouse model
to test the efficacy of the combination therapy in vivo. A
10-day treatment with panobinostat and bortezomib was
well tolerated and suppressed tumor growth significantly
(Figure 2). The p values at day 12 were 0.0283 for the
control group and combination group, 0.0283 for the
bortezomib group and combination group, and 0.0472
for the panobinostat group and combination group.
The average tumor size at day 15 was 520 ± 175 mm3
(mean ± SE) in the vehicle-treated mice and was 266 ±
39 mm3 in the combination-treated mice. Thus the com-
bination of panobinostat and bortezomib was shown to be
effective for suppressing renal cancer growth both in vitro
and in vivo.renal cancer growth effectively. A, MTS assay results (mean ± SD,
ostat alone or with bortezomib and panobinostat together. B, Colony
l media (C) or media containing 50 nM panobinostat (P) and/or 10 nM
Table 1 Combination indexes for the combination of
panobinostat and bortezomib in renal cancer cells
Panobinostat (nM) Bortezomib (nM)
5 10 15
Caki-1
25 0.927 0.581 0.791
50 1.186 0.737 0.808
ACHN
25 0.557 0.458 0.553
50 0.463 0.394 0.544
769-P
25 1.074 0.803 0.946
50 1.41 0.512 0.519
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apoptosis
The combination increased the annexin-V fluorescence
intensity (up to 19.4-fold compared with control vehicle)
(Figure 3A) and also increased the number of the cells
in the sub-G1 fraction (up to 70.5%) (Figure 3B). Thus
the combination of panobinostat and bortezomib was
demonstrated to induce apoptosis in renal cancer cells.
Combination of panobinostat and bortezomib induced ER
stress and ubiquitinated protein accumulation
synergistically
The combination induced ER stress synergistically as
indicated by the increased expression of ER stress
markers such as GRP78, HSP70, ERp44, and (except
in 769-P cells) Ero1-Lα (Figure 4A). As expected, theFigure 2 The combination of panobinostat and bortezomib
suppressed tumor growth in vivo. A murine subcutaneous tumor
model was made using Caki-1 cells, and the control group received
intraperitoneal injections of DMSO, while other groups received
either panobinostat (2 mg/kg) or bortezomib (60 μg/kg) or both.
Injections were given once a day, 5 days a week, for 2 weeks. The
10-day treatment was well tolerated and suppressed tumor growth
significantly (mean ± SE; p = 0.0283 at day 12).combination induced ubiquitinated protein accumula-
tion synergistically (Figure 4B): in Caki-1 and 769-P
cells, 10 nM bortezomib alone did not cause ubiquiti-
nated proteins to accumulate but in combination with
50 nM panobinostat increased the accumulation of
ubiquitinated proteins markedly. In ACHN cells, 10 nM
bortezomib caused ubiquitinated protein accumulation
and the accumulation was synergistically enhanced by
50 nM panobinostat. Acetylation of α-tubulin by panobi-
nostat is consistent with HDAC6 inhibition because
α-tubulin is one of the important substrates of HDAC6.
Interestingly, the combination also enhanced the acetyl-
ation of histone and α-tubulin synergistically in Caki-1 and
ACHN cells. In 769-P cells, the combination enhanced the
acetylation of α-tubulin but not that of histone.
Histone acetylation was a consequence of ubiquitinated
protein accumulation
We then investigated the relationship between histone
acetylation and ubiquitinated protein accumulation. Pano-
binostat caused histone acetylation in a dose-dependent
fashion in all the cell lines but did not induce ubiquiti-
nated protein accumulation (Figure 5A). Bortezomib, on
the other hand, caused both ubiquitinated protein accu-
mulation and histone acetylation in a dose-dependent
fashion in Caki-1 and ACHN cells but did not cause
histone acetylation in 769-P cells (Figure 5B). This is in
accordance with the result that the combination did not
enhance histone acetylation in 769-P cells despite inducing
ubiquitinated protein accumulation in them (Figure 4B).
We inferred from these results that the histone acetylation
the combination caused in Caki-1 and ACHN cells was a
consequence of ubiquitinated protein accumulation.
Discussion
Inducing ER stress and ubiquitinated protein accumula-
tion is a novel approach to cancer therapy. The combin-
ation of an HDAC inhibitor and bortezomib is one of
the combinations that might be expected to do it. The
combination of panobinostat and bortezomib has recently
been investigated mainly in hematological malignancies
[11,12]. It has been reported that the combination of
bortezomib and the HDAC inhibitor suberoylanilide
hydroxamic acid inhibits renal cancer growth by causing
accumulation of ubiquitinated proteins and histone acetyl-
ation [13], but that study did not show the relationship
between ubiquitinated protein accumulation and histone
acetylation. In the present study, using panobinostat, a
more potent HDAC inhibitor (acting at nanomolar con-
centrations, whereas suberoylanilide hydroxamic acid acts
at micromolar concentrations), we investigated the effect
of the bortezomib-panobinostat combination on renal
cancer growth as well as further mechanisms of the
combination of bortezomib and an HDAC inhibitor.
Figure 3 (See legend on next page.)
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Figure 3 The combination of panobinostat and bortezomib induced apoptosis in renal cancer cells. Cells were treated for 48 hours with
50 nM panobinostat with or without 10 nM bortezomib. The combination increased the annexin-V-FITC fluorescence intensity (A) and increased
the number of the cells in the sub-G1 fraction (B). Relative annexin-V-FITC fluorescence intensity (control = 1) is shown in the insets. White, control; red,
treated. The percentage of cells in the sub-G1 fraction is shown in the graph. Representative results are shown.
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function and increasing the amount of unfolded proteins
[4]. We think that bortezomib inhibits degradation of
unfolded proteins increased by panobinostat, which in-
duces ER stress and ubiquitinated protein accumulation.
Accumulation of unfolded proteins, or ER stress, acti-
vates a signaling pathway known as the unfolded protein
response (UPR), which leads to increased transcription
of ER folding and quality-control factors [14]. In the
present study we showed the induction of ER stress by
detecting the increased expression of UPR-related pro-
teins: GRP78, HSP70, Ero1-Lα, and ERp44. GRP78 is a
master regulator for ER stress because of its role as a
major ER chaperone as well as its ability to control the
activation of UPR signaling [15]. HSP70 is a molecular
chaperone localized in the cytoplasm but associated withFigure 4 The combination therapy induced ER stress and histone ace
combination of panobinostat and bortezomib induced ER stress synergistic
and Ero1-Lα (A). It also caused ubiquitinated protein accumulation in all th
acetylation in Caki-1 and ACHN cells. In 769-P cells, the combination enhance
in the Caki-1 results in parts A and B indicate that the order of the bands hasthe regulation of the UPR by forming a stable protein
complex with the cytosolic domain of inositol-requiring
enzyme 1α [16]. Ero1-Lα regulates oxidative protein
folding by selectively oxidizing protein disulfide isomer-
ase [17], one of the key players in the control of disulfide
bond formation [18]. ERp44 forms mixed disulfides with
Ero1-Lα and may be involved in the control of oxidative
protein folding [19]. The increased expression of these
ER stress-related proteins thus confirmed that ER stress
was induced by the combination of panobinostat and
bortezomib.
Acetylation of α-tubulin, one of the important sub-
strates of HDAC6 [20], is consistent with the inhibition
of HDAC6 by panobinostat. Interestingly, panobinostat
itself did not cause marked ER stress even though it
inhibited HDAC6 function. This may be because thetylation in renal cancer cells. The 48-hour treatment with the
ally as indicated by the increased expression of GRP78, HSP70, ERp44,
e cell lines synergistically and enhanced histone and also α-tubulin
d the acetylation of α-tubulin but not that of histone (B). The dashed lines
been rearranged from the original gel.
Figure 5 Histone acetylation was a consequence of ubiquitinated protein accumulation. A, 48-hour treatment with panobinostat caused
dose-dependent histone acetylation in all the cell lines but did not cause ubiquitinated protein accumulation. B, 48-hour treatment with bortezomib,
on the other hand, caused both histone acetylation and ubiquitinated protein accumulation in Caki-1 and ACHN cells and caused only ubiquitinated
protein accumulation in 769-P cells.
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degraded immediately by the proteasome if its function
is not suppressed. This explanation is consistent with
the result that panobinostat induced marked ER stress
only when combined with bortezomib.
The combination induced ubiquitinated protein ac-
cumulation synergistically. This is because panobinostat
increased unfolded proteins, which were then ubiquiti-
nated, and bortezomib inhibited their degradation. The
ubiquitinated protein accumulation is also in accordance
with the above-discussed enhanced ER stress induced by
the combination because ER stress is induced by the accu-
mulation of unfolded proteins in the cell, and many of
these unfolded proteins are ubiquitinated. Not only are
ubiquitinated proteins themselves toxic to tumor cells [3],
some of them may be important molecules for cancer cell
survival (such as transcription factors and signal transduc-
tion molecules) that have lost their function because of
unfolding and ubiquitination, presumably leading to the
inhibition of multiple signal transduction pathways. Fur-
thermore, the inhibition of NF-kB is thought to play an
important role in the combination therapy with pano-
binostat and bortezomib because of the accumulation of
undegraded IkB, a suppressor of NF-kB [21]. Jiang XJ
et al. reported that the combination of panobinostat andbortezomib activated caspases and down-regulated
antiapoptotic proteins such as XIAP and Bcl-2 through
inhibition of the AKT and NF-kB pathways [11]. The com-
bination is thus thought to inhibit cancer growth by diverse
mechanisms other than the induction of ER stress and
ubiquitinated protein accumulation.
In Caki-1 and ACHN cells the combination of panobi-
nostat and bortezomib not only caused ubiquitinated pro-
tein accumulation but also enhanced histone acetylation.
In these cell lines, panobinostat alone caused histone
acetylation but not ubiquitinated protein accumulation,
whereas bortezomib alone induced both ubiquitinated
protein accumulation and histone acetylation. We there-
fore think the histone acetylation in these cell lines is
a consequence of ubiquitinated protein accumulation,
which is consistent with the results of a previous
study using prostate cancer cells [22]. In 769-P cells,
on the other hand, the combination enhanced ubiquiti-
nated protein accumulation but not histone acetylation.
This is, however, also in accordance with the result that
bortezomib alone did not cause histone acetylation in
769-P cells. In Caki-1 and ACHN cells, HDAC function
decreased by ubiquitination may be one explanation. In
769-P cells, bortezomib alone seems to even decrease his-
tone acetylation. Ubiquitination may result in the HDAC
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transferase activity there. However, further study will be
needed to clarify the exact mechanism of this decreased
histone acetylation.
The combination of panobinostat and bortezomib
has also been tested clinically, mainly in patients with
hematological malignancies. In the most recent phase-II
study enrolling 55 patients with relapsed and bortezomib-
refractory myeloma [23], the patients were treated with
eight 3-week cycles of 20 mg panobinostat three times a
week and 1.3 mg/m2 bortezomib twice a week with 20 mg
of dexamethasone four times a week on weeks 1 and 2. If
the patients showed clinical benefit, then they were treated
with 6-week cycles of panobinostat three times a week
and bortezomib once a week on weeks 1, 2, and 4 with
dexamethasone on the days of and after bortezomib. In
that study the overall response rate was 34.5%, the clinical
benefit rate was 52.7%, and grade 3 or 4 adverse events
were thrombocytopenia (63.6%), fatigue (20.0%), and diar-
rhea (20.0%). Two limitations of our in-vivo study are that
it could not provide information about whether the doses
we used in mice were equivalent to those used in humans
and that it lacked a proper assessment of side effects. This
study is, however, the first to show the beneficial
combined effect of panobinostat and bortezomib in
renal cancer cells, and it provides a basis for testing
the combination in clinical settings.
Conclusions
Panobinostat inhibits renal cancer growth by synergizing
with bortezomib to induce ER stress and ubiquitinated
protein accumulation. Histone acetylation may be another
important mechanism of action. This is the first study to
demonstrate the combination’s effect on renal cancer cells
both in vitro and in vivo, and it provides a basis for testing
the combination in patients with advanced renal cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AS contributed to design and interpretation of all experiments, drafting of
the manuscript and execution of western blotting, colony formation assay
and animal experiments. TA collected and assembled data and performed
MTS assay, cell cycle analysis, annexin-V assay and animal experiments.
MI participated in the study design, performed statistical analysis and helped
to draft the manuscript. KI contributed to design and interpretation of all
experiments and drafting of the manuscript. TA participated in the study
design and coordination and helped to draft the manuscript. All authors read
and approved the final manuscript.
Received: 21 March 2014 Accepted: 26 August 2014
Published: 30 August 2014
References
1. Liu Y, Ye Y: Proteostasis regulation at the endoplasmic reticulum: a new
perturbation site for targeted cancer therapy. Cell Res 2011, 21:867–883.
2. Tabas I, Ron D: Integrating the mechanisms of apoptosis induced by
endoplasmic reticulum stress. Nat Cell Biol 2011, 13:184–190.3. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L:
Simultaneous inhibition of hsp 90 and the proteasome promotes
protein ubiquitination, causes endoplasmic reticulum-derived cytosolic
vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004,
3:551–566.
4. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K,
Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K: Inhibition of
histone deacetylase 6 acetylates and disrupts the chaperone function of
heat shock protein 90: a novel basis for antileukemia activity of histone
deacetylase inhibitors. J Biol Chem 2005, 280:26729–26734.
5. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic
pathway: destruction for the sake of construction. Physiol Rev 2002,
82:373–428.
6. Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia
Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F,
Prince HM: Panobinostat activity in both bexarotene-exposed and -naïve
patients with refractory cutaneous T-cell lymphoma: results of a phase II
trial. Eur J Cancer 2013, 49:386–394.
7. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR,
Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial
S: Phase II trial of the pan-deacetylase inhibitor panobinostat as a single
agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma
2012, 53:1820–1823.
8. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M,
Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y: Phase I
dose-escalating study of panobinostat (LBH589) administered intravenously
to Japanese patients with advanced solid tumors. Invest New Drugs 2012,
30:1950–1957.
9. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA: A
phase II trial of panobinostat, a histone deacetylase inhibitor, in the
treatment of patients with refractory metastatic renal cell carcinoma.
Cancer Invest 2011, 29:451–455.
10. Kane RC, Farrell AT, Sridhara R, Pazdur R: United States Food and Drug
Administration approval summary: bortezomib for the treatment of
progressive multiple myeloma after one prior therapy. Clin Cancer Res
2006, 12:2955–2960.
11. Jiang XJ, Huang KK, Yang M, Qiao L, Wang Q, Ye JY, Zhou HS, Yi ZS, Wu FQ,
Wang ZX, Zhao QX, Meng FY: Synergistic effect of panobinostat and
bortezomib on chemoresistant acute myelogenous leukemia cells via
AKT and NF-κB pathways. Cancer Lett 2012, 326:135–142.
12. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A,
Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN: Role of CAAT/
enhancer binding protein homologous protein in panobinostat-mediated
potentiation of bortezomib-induced lethal endoplasmic reticulum stress in
mantle cell lymphoma cells. Clin Cancer Res 2010, 16:4742–4754.
13. Sato A, Asano T, Ito K, Sumitomo M, Asano T: Suberoylanilide hydroxamic
acid (SAHA) combined with bortezomib inhibits renal cancer growth by
enhancing histone acetylation and protein ubiquitination synergistically.
BJU Int 2012, 109:1258–1268.
14. Mori K: Tripartite management of unfolded proteins in the endoplasmic
reticulum. Cell 2000, 101:451–454.
15. Lee AS: The ER chaperone and signaling regulator GRP78/BiP as a
monitor of endoplasmic reticulum stress. Methods 2005, 35:373–381.
16. Gupta S, Deepti A, Deegan S, Lisbona F, Hetz C, Samali A: HSP72 protects cells
from ER stress-induced apoptosis via enhancement of IRE1alpha-XBP1
signaling through a physical interaction. PLoS Biol 2010, 8:e1000410.
17. Mezghrani A, Fassio A, Benham A, Simmen T, Braakman I, Sitia R:
Manipulation of oxidative protein folding and PDI redox state in
mammalian cells. EMBO J 2001, 20:6288–6296.
18. Bulleid NJ, Freedman RB: Defective co-translational formation of disulphide
bonds in protein disulphide-isomerase-deficient microsomes. Nature 1988,
335:649–651.
19. Anelli T, Alessio M, Mezghrani A, Simmen T, Talamo F, Bachi A, Sitia R:
ERp44, a novel endoplasmic reticulum folding assistant of the
thioredoxin family. EMBO J 2002, 21:835–844.
20. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M,
Wang XF, Yao TP: HDAC6 is a microtubule-associated deacetylase.
Nature 2002, 417:455–458.
21. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X,
Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG,
Hideshima T, Anderson KC: Molecular sequelae of proteasome inhibition
Sato et al. BMC Urology 2014, 14:71 Page 9 of 9
http://www.biomedcentral.com/1471-2490/14/71in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002,
99:14374–14379.
22. Sato A, Asano T, Ito K, Asano T: Vorinostat and bortezomib synergistically
cause ubiquitinated protein accumulation in prostate cancer cells.
J Urol 2012, 188:2410–2418.
23. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto
C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S: PANORAMA
2: panobinostat in combination with bortezomib and dexamethasone in
patients with relapsed and bortezomib-refractory myeloma. Blood 2013,
122:2331–2337.
doi:10.1186/1471-2490-14-71
Cite this article as: Sato et al.: Panobinostat synergizes with bortezomib
to induce endoplasmic reticulum stress and ubiquitinated protein
accumulation in renal cancer cells. BMC Urology 2014 14:71.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
